Oragenics moves ahead with SARS-CoV-2 vaccine

By The Science Advisory Board staff writers

October 6, 2020 -- Oragenics is moving ahead with its SARS-CoV-2 vaccine called Terra CoV-2 with the support of the U.S. Food and Drug Administration (FDA).

The company plans to file an investigational new drug (IND) application for Terra CoV-2 by the end of the first quarter of 2021 and to begin a phase I study in the second quarter, it said. The FDA has requested that Oragenics include additional preclinical animal data in its IND, according to the firm.

Oragenics acquired a nonexclusive license for Terra CoV-2 from the U.S. National Institutes of Health (NIH) in March.

Copyright © 2020 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here